Clinical Trial Detail

NCT ID NCT03833180
Title A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors VelosBio Inc.
Indications

Waldenstroem's macroglobulinemia

chronic lymphocytic leukemia

B-cell lymphoma

B-cell acute lymphoblastic leukemia

acute myeloid leukemia

marginal zone B-cell lymphoma

mantle cell lymphoma

Burkitt lymphoma

lymphoplasmacytic lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

VLS-101

Age Groups: adult senior

No variant requirements are available.